Droplet digital PCR as an alternative to FISH for MYCN amplification detection in human neuroblastoma FFPE samples [PDF]
BMC Cancer, 2019 Background MYCN amplification directly correlates with the clinical course of neuroblastoma and poor patient survival, and serves as the most critical negative prognostic marker.
Dinesh Babu Somasundaram +7 more
doaj +2 more sources
Effects of preoperative chemotherapy on neuroblastoma with MYCN amplification: a surgeon's perspective. [PDF]
World J Pediatr Surg, 2020 Background Preoperative chemotherapy plays an important role in the surgical management of unresectable neuroblastoma. Its response to chemotherapy has been variable due to the tumor’s heterogeneity.
Chui C.
europepmc +5 more sources
Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group [PDF]
European Journal of Cancer, 2020 Hiroyuki Shimada +2 more
exaly +2 more sources
Extracellular Vesicle-Based Method for Detecting MYCN Amplification Status of Pediatric Neuroblastoma. [PDF]
Cancers (Basel), 2022 SIMPLE SUMMARY: MYCN gene amplification, the strongest prognostic marker of aggressive neuroblastoma, is detected on invasive biopsy tissues. This study aimed to establish a less invasive method to detect MYCN status based on MYCN mRNA contents in large ...
Panachan J +14 more
europepmc +2 more sources
MYCN gene amplification in rhabdomyosarcoma [PDF]
Cancer, 1994 Amplification of the MYCN oncogene, formerly known as N-myc, has been seen in several malignant tumors, particularly neuroblastoma, where its association with a poor clinical outcome is the clearest example of a clinically relevant oncogene mutation in any human cancer.The incidence and clinical significance of MYCN amplification in rhabdomyosarcoma ...
D, Driman +4 more
openaire +2 more sources
MYCN Amplification, along with Wild-Type RB1 Expression, Enhances CDK4/6 Inhibitors' Efficacy in Neuroblastoma Cells. [PDF]
Int J Mol Sci, 2023 Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB's mutation landscape, optimizing individualized therapies is still challenging.
De Rosa P +8 more
europepmc +2 more sources
Proteogenomic characterization of cholangiocarcinoma
Hepatology, EarlyView., 2022 Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng +18 more
wiley +1 more source
MYCN Amplifications and Metabolic Rewiring in Neuroblastoma
Cancers, 2023 Cancer is a disease caused by (epi)genomic and gene expression abnormalities and characterized by metabolic phenotypes that are substantially different from the normal phenotypes of the tissues of origin. Metabolic reprogramming is one of the key features of tumors, including those established in the human nervous system.
Marialena Pouliou +6 more
openaire +3 more sources
BMC Pediatrics, 2020 Background Neuroblastoma patients with MYCN amplification are associated with poor prognosis. However, the prognostic relevance of MYCN associated genes in neuroblastoma is unclear. Methods The expression profiles of MYCN associated genes were identified
Haiwei Wang +4 more
doaj +1 more source
MYCN in Neuroblastoma: “Old Wine into New Wineskins”
Diseases, 2021 MYCN Proto-Oncogene, BHLH Transcription Factor (MYCN) has been one of the most studied genes in neuroblastoma. It is known for its oncogenetic mechanisms, as well as its role in the prognosis of the disease and it is considered one of the prominent ...
Maria Braoudaki +3 more
doaj +1 more source